EICHORCondition: Atopic Dermatitis · Sponsor: Amgen
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Phoenix Childrens Hosptial | Phoenix, Arizona, United States | — |
| Medical Advancement Centers of Arizona | Tempe, Arizona, United States | — |
| Dermatology Trial Associates | Bryant, Arkansas, United States | — |
| Little Rock Allergy and Asthma Clinical Research Center | Little Rock, Arkansas, United States | — |
| University of California Irvine | Irvine, California, United States | — |
| University of California Los Angeles | Los Angeles, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| Manlio Dermatology | Kissimmee, Florida, United States | — |
| Palm Springs Community Health Center | Miami, Florida, United States | — |
| ARA Professionals Limited Liability Corporation | Miami, Florida, United States | — |
| Deluxe Health Care LLC | Miami Lakes, Florida, United States | — |
| Bluegrass Allergy Care | Lexington, Kentucky, United States | — |
+ 65 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05633355